Genetic polymorphisms of CYP2C8 in Japanese population

被引:61
作者
Nakajima, M
Fujiki, Y
Noda, K
Ohtsuka, H
Ohkuni, H
Kyo, S
Inoue, M
Kuroiwa, Y
Yokoi, T
机构
[1] Kanazawa Univ, Fac Pharmaceut Sci, Div Drug Metab, Kanazawa, Ishikawa 9200934, Japan
[2] Kanazawa Univ, Sch Med, Dept Obstet & Gynecol, Kanazawa, Ishikawa 9200934, Japan
[3] Medca Japan Co Ltd, Saitama, Japan
[4] Fuji Biomedix Co Ltd, Saitama, Japan
关键词
D O I
10.1124/dmd.31.6.687
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
CYP2C8 plays important roles in metabolizing therapeutic drugs and endogenous compounds. Although genetic polymorphisms of CYP2C8 were reported, there is little information on CYP2C8 polymorphisms in the Japanese population. In the present study, we screened for previously described polymorphisms in the coding region of this gene using polymerase chain reaction (PCR)-restriction fragment length polymorphism or allele specific-PCR analyses. Eleven polymorphisms of CYP2C8*2 (I269F), CYP2C8*3 (R139K, K399R), CYP2C8*4 (I264M), CYP2C8*5 (frameshift), T130N, E154D, N193K, K249R, L390S, P404A, and H411L have been comprehensively investigated in at least 200 Japanese individuals. A single subject was heterozygous for CYP2C8*5, and the allele frequency was calculated as 0.0025. The other single nucleotide polymorphisms (SNPs) were not found in the Japanese subjects in the present study. Thus, it appears that the frequencies of these alleles in Japanese are extremely low. In addition, concerning the SNPs of T130N, E154D, N193K, K249R, and H411L, it remains clear that these alleles exist as polymorphisms or represent sequence errors or cloning artifacts. Although several SNPs such as CYP2C8*2, CYP2C8*3, CYP2C8*4, and P404A have been reported to reduce the enzymatic activity, pharmacokinetic abnormalities of drugs metabolized by polymorphic CYP2C8 might be rare in Japanese.
引用
收藏
页码:687 / 690
页数:4
相关论文
共 19 条
  • [1] CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6α-hydroxylase activity in human liver microsomes
    Bahadur, N
    Leathart, JBS
    Mutch, E
    Steimel-Crespi, D
    Dunn, SA
    Gilissen, R
    Van Houdt, J
    Hendrickx, J
    Mannens, G
    Bohets, H
    Williams, FM
    Armstrong, M
    Crespi, CL
    Daly, AK
    [J]. BIOCHEMICAL PHARMACOLOGY, 2002, 64 (11) : 1579 - 1589
  • [2] Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid
    Dai, D
    Zeldin, DC
    Blaisdell, JA
    Chanas, B
    Coulter, SJ
    Ghanayem, BI
    Goldstein, JA
    [J]. PHARMACOGENETICS, 2001, 11 (07): : 597 - 607
  • [3] CHARACTERIZATION OF CDNAS, MESSENGER-RNAS, AND PROTEINS RELATED TO HUMAN-LIVER MICROSOMAL CYTOCHROME-P-450 (S)-MEPHENYTOIN 4'-HYDROXYLASE
    GED, C
    UMBENHAUER, DR
    BELLEW, TM
    BORK, RW
    SRIVASTAVA, PK
    SHINRIKI, N
    LLOYD, RS
    GUENGERICH, FP
    [J]. BIOCHEMISTRY, 1988, 27 (18) : 6929 - 6940
  • [4] CDNA AND AMINO-ACID-SEQUENCES OF 2 MEMBERS OF THE HUMAN P450IIC GENE SUBFAMILY
    KIMURA, S
    PASTEWKA, J
    GELBOIN, HV
    GONZALEZ, FJ
    [J]. NUCLEIC ACIDS RESEARCH, 1987, 15 (23) : 10053 - 10054
  • [5] Klose TS, 1999, J BIOCHEM MOL TOXIC, V13, P289, DOI 10.1002/(SICI)1099-0461(1999)13:6<289::AID-JBT1>3.0.CO
  • [6] 2-N
  • [7] SEQUENCE OF A HUMAN LIVER CYTOCHROME-P-450 CDNA CLONE
    KOLYADA, AY
    [J]. NUCLEIC ACIDS RESEARCH, 1990, 18 (18) : 5550 - 5550
  • [8] Mück W, 2000, CLIN PHARMACOKINET, V39, P99
  • [9] Participation of CYP2C8 in retinoic acid 4-hydroxylation in human hepatic microsomes
    Nadin, L
    Murray, M
    [J]. BIOCHEMICAL PHARMACOLOGY, 1999, 58 (07) : 1201 - 1208
  • [10] Nagata Kiyoshi, 2002, Drug Metab Pharmacokinet, V17, P167, DOI 10.2133/dmpk.17.167